Naujų prostatos specifinio antigeno izoformų reikšmė ankstyvajai prostatos vėžio diagnostikai

2021 ◽  
Author(s):  
◽  
Marija Barisienė
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen

Significance of new prostate-specific antigen isoforms for early diagnosis of prostate cancer

scholarly journals Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target

2018 ◽  
Vol 12 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Athanasios Skarmoutsos ◽  
Ioannis Skarmoutsos ◽  
Ioannis Katafigiotis ◽  
Elisavet Tataki ◽  
Athina Giagini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Characteristic Curve ◽  
Specific Antigen ◽  
Predictive Ability ◽  
Platelet Derived Growth Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Transrectal Biopsy

Introduction: Although the prostate specific antigen revolutionized the diagnosis of prostate cancer (PCa), it has its limitations. We prospectively examined the potential use of the platelet-derived growth factor-BB (PDGF-BB) as a urine biomarker for the early diagnosis of PCa. Materials and Methods: The urine samples of 118 patients were collected after a prostatic massage and all the patients subsequently underwent ultrasound-guided transrectal biopsy. PDGF-BB was detected in the urine by enzyme-linked immunosorbent assay. Results: Patients with PCa had greater levels of prostate specific antigen and PDGF-BB. Receiver operating characteristic curve analysis showed that the optimal cut-of of PDGF-BB for the prediction of PCa was 1,504.9 with a sensitivity of 60% and a specificity of 51.3%. For a 100 unit increase in PDGF-BB, the likelihood for PCa increased about 4%. Conclusion: PDGF-BB showed a significant predictive ability for PCa. Detection of PDGF-BB in urine with Elisa was easy and improved our diagnostic accuracy in the diagnosis of PCa.

scholarly journals PSA screening for prostate cancer

2017 ◽  
Vol 63 (8) ◽  
pp. 722-725 ◽  
Author(s):  
Marcus V. Sadi
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Low Grade ◽  
Psa Screening ◽  
Psa Testing ◽  
Baseline Values

Summary Screening of prostate cancer with prostate-specific antigen (PSA) is a highly controversial issue. One part of the controversy is due to the confusion between population screening and early diagnosis, another derives from problems related to the quality of existing screening studies, the results of radical curative treatment for low grade tumors and the complications resulting from treatments that affect the patient’s quality of life. Our review aimed to critically analyze the current recommendations for PSA testing, based on new data provided by the re-evaluation of the ongoing studies and the updated USPSTF recommendation statement, and to propose a more rational and selective use of PSA compared with baseline values obtained at an approximate age of 40 to 50 years.

Value of Prostate Specific Antigen in Early Diagnosis of Prostate Cancer: Study of Men Born in 1913

1995 ◽  
Vol 154 (4) ◽  
pp. 1386-1389 ◽  
Author(s):  
Gosta Tibblin ◽  
Lennart Welin ◽  
Reinhold Bergstrom ◽  
Gunnar Ronquist ◽  
Bo-Johan Norlen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Cancer Study ◽  
Prostate Cancer Study

Value of Prostate Specific Antigen in Early Diagnosis of Prostate Cancer

1995 ◽  
pp. 1386-1389 ◽  
Author(s):  
Gosta Tibblin ◽  
Lennart Welin ◽  
Reinhold Bergstrom ◽  
Gunnar Ronquist ◽  
Bo-Johan Norlen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen

scholarly journals Au–Ag assembled on silica nanoprobes for visual semiquantitative detection of prostate-specific antigen

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Hyung-Mo Kim ◽  
Jaehi Kim ◽  
Jaehyun An ◽  
Sungje Bock ◽  
Xuan-Hung Pham ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Test Line ◽  
Specific Antigen ◽  
Test Strip ◽  
Clinical Samples ◽  
Color Intensity ◽  
Ag Nps ◽  
Relative Standard

Abstract Background Blood prostate-specific antigen (PSA) levels are widely used as diagnostic biomarkers for prostate cancer. Lateral-flow immunoassay (LFIA)-based PSA detection can overcome the limitations associated with other methods. LFIAbased PSA detection in clinical samples enables prognosis and early diagnosis owing to the use of high-performance signal reporters. Results Here, a semiquantitative LFIA platform for PSA detection in blood was developed using Au–Ag nanoparticles (NPs) assembled on silica NPs (SiO2@Au–Ag NPs) that served as signal reporters. Synthesized SiO2@Au–Ag NPs exhibited a high absorbance at a wide wavelength range (400–800 nm), with a high scattering on nitrocellulose membrane test strips. In LFIA, the color intensity of the test line on the test strip differed depending on the PSA concentration (0.30–10.00 ng/mL), and bands for the test line on the test strip could be used as a standard. When clinical samples were assessed using this LFIA, a visual test line with particular color intensity observed on the test strip enabled the early diagnosis and prognosis of patients with prostate cancer based on PSA detection. In addition, the relative standard deviation of reproducibility was 1.41%, indicating high reproducibility, and the signal reporter showed good stability for 10 days. Conclusion These characteristics of the signal reporter demonstrated the reliability of the LFIA platform for PSA detection, suggesting potential applications in clinical sample analysis.

Sign in / Sign up

Export Citation Format

Share Document